Pharmaceutical - Johnson & Johnson, Antibiotics and Infectious diseases


Popular Filters

Janssen sets up new group targeting unmet global health needs

Janssen sets up new group targeting unmet global health needs


US health care giant Johnson & Johnson’s Janssen companies are forming Janssen Global Public Health,…

Anti-viralsAntibiotics and Infectious diseasesJanssenJohnson & JohnsonPharmaceuticalResearch

Four medicines recommended for approval by EMA/CHMP

Four medicines recommended for approval by EMA/CHMP


Following regular monthly meeting of the European Medicines Agency’s Committee for Medicinal Products…

AlconAntibiotics and Infectious diseasesComtriqDermatologicalsEuropeGaldermaJanssen-CilagJohnson & JohnsonMirvasoNovartisOncologyOphthalmicsPharmaceuticalRegulationSirturoTMC Pharma Services

TAC puts pressure on Janssen finalize development of TB drug bedaquiline


The current standard of care for multi-drug resistant tuberculosis (MDR-TB) consists of poorly tested…

Antibiotics and Infectious diseasesbedaquilineJanssenJohnson & JohnsonPharmaceuticalPoliticsResearchRest of the World

Rise in infections means hepatitis C market is expected to peak at $15.5 billion in 2022


The hepatitis C market is forecast to increase by a massive 230% in the next nine years, according to…

AbbVieAntibiotics and Infectious diseasesBristol-Myers SquibbGilead SciencesGlobalJohnson & JohnsonMarkets & MarketingPharmaceuticalsofosbuvir

Pharmstandard to produce Janssen's anti-TB drugs in Russia; Nyuvak deal


JSC Pharmstandard (PHST: MM), one of Russia's largest pharmaceutical producers, has signed an agreement…

Antibiotics and Infectious diseasesbedaquilineEuropeJanssenJohnson & JohnsonMarkets & MarketingNyuvakOncologyPharmaceuticalPharmstandardProductionquisinostat

Janssen's TB drug Sirturo gains US FDA approval


The US Food and Drug Administration has granted accelerated approval for US health care major Johnson…

Antibiotics and Infectious diseasesbedaquilineJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSirturo

Public Citizen urges FDA to reject accelerated approval for Janssen's bedaquiline


The US Food and Drug Administration should not approve the anti-tuberculosis drug bedaquiline from Janssen,…

Antibiotics and Infectious diseasesbedaquilineJohnson & JohnsonNorth AmericaPharmaceuticalRegulation

FDA staffers seem to back safety of Janssen bedaquiline (Sirturo)


Ahead of the November 28 meeting of the US Food and Drug Administration's Anti-Infective Drugs Advisory…

Antibiotics and Infectious diseasesbedaquilineJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationRespiratory and PulmonarySirturo

Red tape delaying access to new TB drug in South Africa


South Africa's drug regulatory authority is placing unreasonable hurdles in the way of desperately ill…

Antibiotics and Infectious diseasesbedaquilineJohnson & JohnsonPharmaceuticalRegulationRest of the World

Janssen-Cilag files for EU approval of bedaquiline in MDR-TB


Johnson & Johnson (NYSE: JNJ) Belgium-based subsidiary Janssen-Cilag International submitted a Marketing…

Antibiotics and Infectious diseasesbedaquilinedelamanidEuropeJanssen-CilagJohnson & JohnsonOtsukaPharmaceuticalRegulation

News briefs: TB drug developments at Jansen and AstraZeneca; NPS/Amgen deal amended


US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Research & Development unit has submitted…

AmgenAntibiotics and Infectious diseasesAstraZenecabedaquilineBiotechnologyCellworkscinacalcetJanssenJohnson & JohnsonLicensingMetabolicsNPS PharmaceuticalsPharmaceuticalRegulationResearch

Back to top